A specialist in cardiovascular disease by training, Isabelle Mahé is Professor of Internal Medicine at Paris Cité University, France. She is Head of the Internal Medicine Department at a teaching hospital (Louis Mourier, Assistance Publique Hôpitaux de Paris, Colombes, France), which includes an oncology unit and a cardiovascular disease unit.
She is chair of the scientific council for the INNOVTE-FCRIN Network (Investigation Network On Venous Thrombo-Embolism) and for a patient association taking anticoagulant (Anticoag PASS S2D). She’s in charge of the transversal topic (cancer associated thrombosis) in the North Paris Cancer University Institute. She has extensive experience in methodology and in clinical trials evaluating anticoagulants in different cardiologic or vascular settings.
Her own research projects have resulted in a better knowledge of anticoagulants in complex patients (renally impaired, elderly and cancer patients). She was leading the international prospective randomised double-blind API-CAT Study (focusing on the extended anticoagulant treatment in patients with cancer-associated thrombosis) published in the New England Journal of Medicine in 2025.
